Results 271 to 280 of about 1,154,039 (314)
Some of the next articles are maybe not open access.
Seminars in Respiratory and Critical Care Medicine, 2018
AbstractAlthough airway inflammation is an intrinsic and key feature of asthma, this response varies in its intensity and translation to clinical characteristics and responsiveness to treatment. The observations that clinical heterogeneity is an important aspect of asthma and a feature that likely dictates and determines responses to treatment in ...
Ravi K, Viswanathan, William W, Busse
openaire +2 more sources
AbstractAlthough airway inflammation is an intrinsic and key feature of asthma, this response varies in its intensity and translation to clinical characteristics and responsiveness to treatment. The observations that clinical heterogeneity is an important aspect of asthma and a feature that likely dictates and determines responses to treatment in ...
Ravi K, Viswanathan, William W, Busse
openaire +2 more sources
Inflammatory Bowel Diseases, 2007
Several biologic agents have been assessed in patients with inflammatory bowel disease (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). Until recently, only infliximab (humanized monoclonal anti-TNF-alpha antibody) had been approved by the Food and Drug Administration (FDA) to induce and maintain remission in patients with active mild to ...
Wojciech, Blonski, Gary R, Lichtenstein
openaire +2 more sources
Several biologic agents have been assessed in patients with inflammatory bowel disease (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). Until recently, only infliximab (humanized monoclonal anti-TNF-alpha antibody) had been approved by the Food and Drug Administration (FDA) to induce and maintain remission in patients with active mild to ...
Wojciech, Blonski, Gary R, Lichtenstein
openaire +2 more sources
The Future of Biological Therapies
Seminars in Cutaneous Medicine and Surgery, 2010The last decade has witnessed a significant advance in the management of refractory moderate-to-severe psoriasis. This advance is the introduction of biological therapies to clinical practice. Three classes of biological therapies have been used. Of the first 2 classes to be introduced, the T-cell inhibitors and tumor necrosis factor (TNF)-alpha ...
Warren, Richard B. +1 more
openaire +3 more sources
Pharmacoeconomics of Biologic Therapy
Immunology and Allergy Clinics of North America, 2017Novel biologic agents have allowed clinicians to achieve improved patient outcomes. Appropriate pharmacoceconomic analyses demand evaluation of all relevant costs, including the treatments, the disease and comorbidities, and costs of alternative treatments, including their short- and long-term side effects.
Don A, Bukstein, Allan T, Luskin
openaire +2 more sources
Biological therapy for psoriasis
British Journal of Hospital Medicine, 2006Psoriasis is a common, chronic immune-mediated skin disorder. Recent advances in the understanding of the immunopathogenesis of psoriasis have led to the development of biological agents designed to target the molecular mechanisms of the condition. These provide new and effective treatments for patients with moderate to severe psoriasis.
Suzanne E, Clements +2 more
openaire +2 more sources
Biologic therapies in dermatology
British Journal of Hospital Medicine, 2013Biologic therapies, the anti-cytokines in particular, have proved to be a significant addition to the dermatologist’s armamentarium for the management of severe skin disease. This article summarizes the mechanism of action, dosage, approved indications, off-label uses and the future of biologic therapies in dermatology.
Chularojanamontri, Leena +1 more
openaire +4 more sources
Biologic therapies for dyslipidemia
Current Atherosclerosis Reports, 2004Biologic therapies involve the utilization of proteins, DNA, antibodies, or other substances derived or synthesized from living tissue for therapeutic effects. There are several biologic therapies in clinical development for the prevention and treatment of atherosclerosis.
openaire +2 more sources
The Immunogenicity of Biologic Therapies
2017Virtually all therapeutic proteins (biologics) elicit an immune response with the consequent production of anti-drug antibodies (ADA). The majority of ADA to therapeutic monoclonal antibodies (mAbs) are directed against the antigen-binding site of the therapeutic mAb, and hence are neutralizing.
Sandra, Garcês, Jocelyne, Demengeot
openaire +2 more sources
Biologic Therapy of Psoriatic Arthritis
Rheumatic Disease Clinics of North America, 2015Biologic medications, therapeutic proteins that inhibit or modulate proinflammatory immune cells and cytokines, have significantly altered clinicians' ability to effectively treat psoriatic arthritis (PsA). The first widely used biologics have been those targeting tumor necrosis factor alpha.
openaire +2 more sources